Published in Cancer Res on May 15, 2006
RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science (2007) 6.70
Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage. Proc Natl Acad Sci U S A (2007) 4.75
BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol (2009) 3.79
NBA1, a new player in the Brca1 A complex, is required for DNA damage resistance and checkpoint control. Genes Dev (2009) 3.23
MERIT40 facilitates BRCA1 localization and DNA damage repair. Genes Dev (2009) 2.49
RAP80 and RNF8, key players in the recruitment of repair proteins to DNA damage sites. Cancer Lett (2008) 1.50
Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS One (2008) 1.43
Push back to respond better: regulatory inhibition of the DNA double-strand break response. Nat Rev Mol Cell Biol (2013) 1.29
Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair. J Biol Chem (2010) 1.26
Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc Natl Acad Sci U S A (2013) 1.21
The many faces of ubiquitinated histone H2A: insights from the DUBs. Cell Div (2008) 1.18
NBA1/MERIT40 and BRE interaction is required for the integrity of two distinct deubiquitinating enzyme BRCC36-containing complexes. J Biol Chem (2011) 1.14
Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor. Mol Cancer Ther (2009) 1.10
ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor. PLoS One (2013) 1.06
BRCA1 tumor suppressor network: focusing on its tail. Cell Biosci (2012) 1.03
Deubiquitylating enzymes and DNA damage response pathways. Cell Biochem Biophys (2013) 1.03
An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer. PLoS One (2012) 0.96
Mutation screening of the MERIT40 gene encoding a novel BRCA1 and RAP80 interacting protein in breast cancer families. Breast Cancer Res Treat (2009) 0.90
BRCC36A is epistatic to BRCA1 in DNA crosslink repair and homologous recombination in Arabidopsis thaliana. Nucleic Acids Res (2010) 0.85
BRCC3 acts as a prognostic marker in nasopharyngeal carcinoma patients treated with radiotherapy and mediates radiation resistance in vitro. Radiat Oncol (2015) 0.80
Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide. Oncotarget (2014) 0.80
Loss of GGN leads to pre-implantation embryonic lethality and compromised male meiotic DNA double strand break repair in the mouse. PLoS One (2013) 0.78
The Lys63-deubiquitylating Enzyme BRCC36 Limits DNA Break Processing and Repair. J Biol Chem (2016) 0.78
ZMYM3 regulates BRCA1 localization at damaged chromatin to promote DNA repair. Genes Dev (2017) 0.77
Regulation of the DNA Damage Response to DSBs by Post-Translational Modifications. Curr Genomics (2010) 0.77
The role of deubiquitinases in breast cancer. Cancer Metastasis Rev (2016) 0.75
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res (2007) 4.95
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med (2005) 3.35
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) (2011) 3.33
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. Mol Cell (2003) 2.90
Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet (2009) 2.85
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet (2012) 2.71
AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene (2004) 2.67
Concern Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci U S A (2003) 2.52
Focus on epithelial ovarian cancer. Cancer Cell (2004) 2.47
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One (2009) 2.37
Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res (2009) 2.33
Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol Cancer Ther (2003) 2.27
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24
A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res (2011) 2.24
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res (2005) 2.22
Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res (2010) 2.19
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res (2010) 2.15
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev (2011) 1.99
Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A (2008) 1.97
PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res (2011) 1.91
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis. Development (2010) 1.86
Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol (2009) 1.84
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
Altered gene expression in morphologically normal epithelial cells from heterozygous carriers of BRCA1 or BRCA2 mutations. Cancer Prev Res (Phila) (2010) 1.80
AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev (2007) 1.75
Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J Proteome Res (2010) 1.75
Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci U S A (2009) 1.75
Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer. Cancer Res (2006) 1.71
Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res (2011) 1.65
Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol (2009) 1.61
Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations. Cancer Biol Ther (2004) 1.58
Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet (2010) 1.56
LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res (2010) 1.55
Perception of differentiation cues by GATA factors in primitive endoderm lineage determination of mouse embryonic stem cells. Dev Biol (2005) 1.49
Telomerase is frequently activated in tumors with microsatellite instability. Cancer Biol Ther (2004) 1.47
Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Mol Cancer Res (2010) 1.46
Comparison of DNA- and RNA-based methods for detection of truncating BRCA1 mutations. Hum Mutat (2002) 1.44
Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk. Hum Mol Genet (2008) 1.43
DNA array-based method for detection of large rearrangements in the BRCA1 gene. Genes Chromosomes Cancer (2002) 1.41
BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research. Breast Cancer Res Treat (2008) 1.40
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res (2012) 1.38
Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways. J Biol Chem (2002) 1.36
The origin recognition complex localizes to telomere repeats and prevents telomere-circle formation. Curr Biol (2007) 1.36
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer (2007) 1.36
Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program's experience. Am J Med Genet C Semin Med Genet (2003) 1.36
Anomalous expression of epithelial differentiation-determining GATA factors in ovarian tumorigenesis. Cancer Res (2003) 1.34
A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibility. Hum Mol Genet (2011) 1.34
Novel glycan biomarkers for the detection of lung cancer. J Proteome Res (2011) 1.33
MLL associates with telomeres and regulates telomeric repeat-containing RNA transcription. Mol Cell Biol (2009) 1.33
Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. Int J Cancer (2006) 1.32
Detection of treatment-induced changes in signaling pathways in gastrointestinal stromal tumors using transcriptomic data. Cancer Res (2009) 1.31
Altered expression of the septin gene, SEPT9, in ovarian neoplasia. J Pathol (2003) 1.31
Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence. Cancer Res (2011) 1.29
Prostate cancer risk assessment program: a 10-year update of cancer detection. J Urol (2007) 1.28
Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis (2013) 1.28
Telomere repeat binding factors TRF1, TRF2, and hRAP1 modulate replication of Epstein-Barr virus OriP. J Virol (2003) 1.27
Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol (2002) 1.26
Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Res Treat (2009) 1.26
Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. Clin Cancer Res (2005) 1.26
Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. Cancer Res (2006) 1.26
Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. Methods Enzymol (2007) 1.24
Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer. Cell Oncol (2007) 1.24
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol (2011) 1.23
WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer (2005) 1.22
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res (2011) 1.22
Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res (2003) 1.21
Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression. Hum Mutat (2006) 1.19
Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene (2002) 1.19
Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes Cancer (2011) 1.18
Predisposition to cancer caused by genetic and functional defects of mammalian Atad5. PLoS Genet (2011) 1.18
Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Res (2007) 1.17
Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci (2003) 1.17
Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2012) 1.17
Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity. Cancer (2002) 1.16
The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. Cancer Res (2008) 1.14
Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol (2009) 1.14
Biological significance of prolactin in gynecologic cancers. Cancer Res (2009) 1.13
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol (2011) 1.12
Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. Cancer Res (2008) 1.11
Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor. Mol Cancer Ther (2009) 1.10
High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors. Genes Chromosomes Cancer (2009) 1.10
Putative telomere-recruiting domain in the catalytic subunit of human telomerase. Mol Cell Biol (2003) 1.09
Linking transcriptional elongation and messenger RNA export to metastatic breast cancers. Cancer Res (2005) 1.09
Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer (2007) 1.09